<p>A list of 779 scaffolds extracted from approved drugs is provided. For each scaffold, the number of approved drugs it represented, the number and the list of targets it was annotated with and the SMILES representation is given. In addition, pairs of drug scaffolds that formed substructure, CSK equivalence, MMP and RECAP-MMP relationships are provided in separate files. Furthermore, drug scaffold pairs that displayed distinct activity profiles and formed one or more types of structural relationships are given.</p
<p>(A) Acridine, (B) Phenanthrene, (C) Quinoxaline, (D) Naphthalene, and (E) Quinoline groups. Below...
Motivation: Different resources exist for experimentally determined and computed 3D-structures of lo...
Additional file 2. Table S1: Common Structural Motif (CSM) Type Distribution and Occurrence per Macr...
A list of 779 scaffolds extracted from approved drugs is provided. For each scaffold, the number of ...
<p>A list of 221 drug-unique scaffolds that represented approved drugs but were not detected in curr...
<p>The entire collection of 23,791 unique ASB scaffolds generated from compounds from Probes and Dru...
<p>On the basis of the assessment of compound and scaffold coverage of human kinome, sets of kinase ...
Analog series were systematically extracted from more than 650 000 bioactive compounds originating f...
Close structural relationships between approved drugs and bioactive compounds were systematically a...
Background: In order to better understand the structural features of natural compounds from traditio...
In medicinal chemistry, it is of central importance to understand structure-activity relationships (...
Natural products (NPs) have evolved over a very long natural selection process to form optimal inter...
Analog series-based (ASB) scaffolds shared between ZINC and ChEMBL (version 22), ZINC and PubChem an...
Identification of meaningful chemical patterns in today´s increasing amounts of high throughput gene...
Establishing structure-activity relationships (SARs) in hit identification during early stage drug d...
<p>(A) Acridine, (B) Phenanthrene, (C) Quinoxaline, (D) Naphthalene, and (E) Quinoline groups. Below...
Motivation: Different resources exist for experimentally determined and computed 3D-structures of lo...
Additional file 2. Table S1: Common Structural Motif (CSM) Type Distribution and Occurrence per Macr...
A list of 779 scaffolds extracted from approved drugs is provided. For each scaffold, the number of ...
<p>A list of 221 drug-unique scaffolds that represented approved drugs but were not detected in curr...
<p>The entire collection of 23,791 unique ASB scaffolds generated from compounds from Probes and Dru...
<p>On the basis of the assessment of compound and scaffold coverage of human kinome, sets of kinase ...
Analog series were systematically extracted from more than 650 000 bioactive compounds originating f...
Close structural relationships between approved drugs and bioactive compounds were systematically a...
Background: In order to better understand the structural features of natural compounds from traditio...
In medicinal chemistry, it is of central importance to understand structure-activity relationships (...
Natural products (NPs) have evolved over a very long natural selection process to form optimal inter...
Analog series-based (ASB) scaffolds shared between ZINC and ChEMBL (version 22), ZINC and PubChem an...
Identification of meaningful chemical patterns in today´s increasing amounts of high throughput gene...
Establishing structure-activity relationships (SARs) in hit identification during early stage drug d...
<p>(A) Acridine, (B) Phenanthrene, (C) Quinoxaline, (D) Naphthalene, and (E) Quinoline groups. Below...
Motivation: Different resources exist for experimentally determined and computed 3D-structures of lo...
Additional file 2. Table S1: Common Structural Motif (CSM) Type Distribution and Occurrence per Macr...